77 related articles for article (PubMed ID: 16114985)
1. Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes?
Dillman RO; Beutel L; Nayak S; Depriest C; Selvan S; Schiltz P
Cancer Biother Radiopharm; 2005 Aug; 20(4):373-8. PubMed ID: 16114985
[TBL] [Abstract][Full Text] [Related]
2. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
Dillman RO; Beutel LD; Barth NM; de Leon C; O'Connor AA; DePriest C; Nayak SK
Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
[TBL] [Abstract][Full Text] [Related]
3. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas.
Dillman R; Barth N; Selvan S; Beutel L; de Leon C; DePriest C; Peterson C; Nayak S
Cancer Biother Radiopharm; 2004 Oct; 19(5):581-8. PubMed ID: 15650450
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.
Dillman RO; Nayak SK; Barth NM; DeLeon C; Schwartzberg LS; Spitler LE; Church C; O'Connor AA; Beutel LD
Cancer Biother Radiopharm; 1998 Jun; 13(3):165-76. PubMed ID: 10850352
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.
Dillman R; Selvan S; Schiltz P; Peterson C; Allen K; Depriest C; McClay E; Barth N; Sheehy P; de Leon C; Beutel L
Cancer Biother Radiopharm; 2004 Oct; 19(5):658-65. PubMed ID: 15650459
[TBL] [Abstract][Full Text] [Related]
8. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.
Dillman RO; DeLeon C; Beutel LD; Barth NM; Schwartzberg LS; Spitler LE; Garfield DH; O'Connor AA; Nayak SK
Crit Rev Oncol Hematol; 2001; 39(1-2):115-23. PubMed ID: 11418308
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma.
Dillman RO; DePriest C; DeLeon C; Barth NM; Schwartzberg LS; Beutel LD; Schiltz PM; Nayak SK
Cancer Biother Radiopharm; 2007 Jun; 22(3):309-21. PubMed ID: 17651037
[TBL] [Abstract][Full Text] [Related]
10. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Berd D; Sato T; Mastrangelo MJ
Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
[TBL] [Abstract][Full Text] [Related]
11. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Dillman RO; Cornforth AN; Nistor GI; McClay EF; Amatruda TT; Depriest C
J Immunother Cancer; 2018 Mar; 6(1):19. PubMed ID: 29510745
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
16. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
17. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.
Durán-Aniotz C; Segal G; Salazar L; Pereda C; Falcón C; Tempio F; Aguilera R; González R; Pérez C; Tittarelli A; Catalán D; Nervi B; Larrondo M; Salazar-Onfray F; López MN
Cancer Immunol Immunother; 2013 Apr; 62(4):761-72. PubMed ID: 23242374
[TBL] [Abstract][Full Text] [Related]
18. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory.
Schirrmacher V
Cancer Immunol Immunother; 2005 Jun; 54(6):587-98. PubMed ID: 15838708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]